Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of reproductive age and its etiology has not been characterized. Growth differentiation factor 8 (GDF8) is a member of the transforming growth factor-β superfamily that plays a critical role in the regulation of ovarian functions. However, the expression pattern of GDF8 in the human ovary is not yet clear. This study examined the cellular distribution of GDF8 and its putative cellular receptors (ACVR2A, ACVR2B, and ALK5) in a series of normal (n = 34) and PCOS ovaries (n = 14). The immunostaining of GDF8, ACVR2A, ACVR2B, and ALK5 was detected in the oocytes regardless of the developmental stage. All these proteins were localized in antral follicles in normal and PCOS ovaries, and the expression of these proteins increased with increasing follicle diameter. A significantly higher expression of GDF8 was detected in the granulosa cells than in the matched theca cells (TCs). These proteins were also localized in the luteal cells of the corpus luteum. Granulosa cells and TCs of large antral follicles in PCOS ovaries display a higher expression of these proteins. The higher expression levels of GDF8 and its functional receptors (ACVR2A, ACVR2B, and ALK5) in antral follicles of PCOS ovaries than those in normal ovaries suggest the possible involvement of dysregulated GDF8 in the pathogenesis of PCOS.
Introduction
Polycystic ovary syndrome (PCOS) affects approximately 5-10% of women of reproductive age and accounts for 75% of anovulatory infertility [1, 2] . This common reproductive disorder is characterized by clinical or biochemical hyperandrogenism, polycystic ovaries on ultrasonography and ovulatory dysfunction [3] . PCOS is the most common cause of anovulatory infertility and menstrual cycle abnormalities because of the arrest of antral follicle growth [4] . Previous research has documented that this heterogeneous endocrine disorder is closely associated with the abnormal secretion of luteinizing hormone (LH), insulin, and androgen, which results in the inhibition of follicle maturation [5] [6] [7] . However, emerging evidence has suggested that several intrinsic growth factors and their signaling are also involved in the development of an aberrant intrafollicular microenvironment that leads to the abnormality of folliculogenesis in PCOS [8] [9] [10] . These follicle developmental abnormalities in PCOS are characterized by disturbed steroidogenesis, abnormal follicle cell proliferation, and immature oocyte [10] [11] [12] .
Recent studies have demonstrated that members of the transforming growth factor-β (TGF-β) superfamily and their functional receptors are expressed by oocytes and ovarian somatic cells in a developmental stage-specific manner and function as pivotal regulators of oocyte maturation and folliculogenesis [13] . Growth differentiation factor 8 (GDF8) is a member of the TGF-β superfamily and plays a critical role in the development and growth of the mammalian skeletal muscular system [14] . Recent studies have demonstrated the role of GDF8 outside the skeletal muscle system in regulating glucose and fat metabolism that is associated with the development of several metabolic disorders, such as obesity, insulin resistance, and diabetes mellitus [15] [16] [17] [18] , which are also the important features in women with PCOS. In the female reproductive system, the expression and potential functions of GDF8 have recently been investigated in the uterus and placenta [19, 20] . Additionally, studies using clinical samples have demonstrated the possible involvement of GDF8 in the pathogenesis of various female disorders including uterine fibroid, pre-eclampsia, and PCOS [19, 21, 22] . Specifically, serum levels of GDF8 were higher in obese women with PCOS than women without PCOS. Our most recent in vitro studies have identified a new role for GDF8 in the regulation of steroidogenesis (increases aromatase/estradiol but decreases steroidogenic acute regulatory protein/progesterone), gonadotropin responsiveness (enhances follicle-stimulating hormone (FSH)-induced aromatase/estradiol but suppresses LH-induced StAR/progesterone), cell proliferation, lysyl oxidase expression and activity, and pentraxin 3 (PTX3) expression in human granulosa-lutein cells [23] [24] [25] [26] [27] . Beyond its role in regulating steroid production, our previous study has shown that GDF8 suppresses human granulosa cell (GC) proliferation [24] . The mature GDF8 proteins are detectable in the follicle fluid obtained from infertile women undergoing in vitro fertilization (IVF) procedures [26, 28] . Additionally, in vitro studies have demonstrated that activin receptor type IIA (ACVR2A), activin receptor type IIB (ACVR2B), and TGF-β receptor type I (ALK5) are the functional receptors that are used to mediate the GDF8-induced cellular action in human granulosa-lutein cells [26] . Using five size-matched populations of isolated preantral follicles, these functional receptors (ACVR2A, ACVR2B, and ALK5) are all consistently expressed throughout each of the follicle groups in human developing follicles [29] , suggesting that GDF8 might play a functional role in the modulation of ovarian follicular function and development. However, whether human ovarian cells express GDF8 is not yet clear. In the present study, we sought to examine the cellular distribution of GDF8 and its putative cellular receptors (ACVR2A, ACVR2B, and ALK5) in a series of normal ovaries and PCOS specimens. Furthermore, we investigated the distribution of the putative cellular receptors, ACVR2A, ACVR2B, and ALK5, to deeply understand the role of GDF8 in the human ovary.
Materials and methods

Study subjects and materials
Ovarian samples from 14 patients with PCOS and 34 women with normal ovaries were used in this study. These tissues were obtained from the Women's hospital, School of Medicine, Zhejiang University with informed consent from every patient, and with approval from the Institutional Review Board and Ethics Committee. This study was carried out in accordance with the approved guidelines from the Zhejiang University Research Ethics Board. Specimens with normal and pathological findings were removed from patients for therapeutic purposes unrelated to this study. Cases identified as PCOS were based on either the clinical history section of the patient's medical record (the revised 2003 Rotterdam consensus criteria) [3] or the pathology report displaying the histological features of the polycystic ovary (fibrotic change of the ovarian cortex and numerous maturing and atretic follicles). The ages of the PCOS patients ranged from 22 to 41 years, with a mean age of 33.4 years. Archived specimens from 34 non-neoplastic ovary samples without histopathological abnormality were selected to serve as normal controls. These cases were clinically reviewed and selected based on regular menstrual cycles; these cases involved patients who had not used hormonal therapy for more than 6 months before surgery. The ages of these patients ranged from 27 to 40 years, with a mean age of 34.8 years. The cycle status of the patients was determined by histological criteria. Most of these patients received surgical oophorectomy during their mid-follicular phase of the menstrual cycle.
Antibodies and reagents
A polyclonal rabbit anti-GDF8 antibody (ab71808), a polyclonal rabbit anti-ALK5 antibody (ab31013), a monoclonal mouse anti-ACVR2A antibody (ab78412), and a polyclonal rabbit anti-ACVR2B antibody (ab128544) were obtained from Abcam Inc. (Cambridge, MA, USA). The horseradish peroxidase (HRP)-conjugated goat anti-rabbit and goat anti-mouse IgGs were obtained from Abcam Inc. DAB, Envision/HRP, blocking agent, and antibody diluent was obtained from Abcam Inc.
Immunohistochemical staining
Tissue samples were fixed in 10% buffered formaldehyde, embedded in paraffin, cut into 5 μm sections and mounted on microscope slides. Sections were then deparaffinized and rehydrated in PBS-T (0.01 M PBS at pH 7.4: KH2PO4 0.02%, N2HPO4 0.29%, KCl 0.02%, 0.8% NaCl, 0.05% BSA, 0.05% Tween-20 and 0.0015% TritonX-100), which was used for all further incubations and washes. Next, the sections were blocked with 50 μl of 3% hydrogen peroxide solution at room temperature for 10 min and rinsed in PBS-T (3 min 
The assessment of the distribution patterns and degree of IHC staining of each target was evaluated using a semiquantitative IRS designed by Remmele and Stegner [30] , calculated by multiplication of optical staining intensity (graded as 0, none; 1, weak; 2, moderate; and 3, strong staining) and the percentage of the positively stained cells (0, =0%; 1, ≤10% of the cells; 2, 11-50% of the cells; 3, 51-80% of the cells; and 4, >80% of the cells). The results are expressed as mean ± SD with "n" indicating sample number. ACVR, activin receptor; ALK5, activin receptor-like kinase receptor 5; GC, granulosa cell; LLC, large luteal cell; SLC, small luteal cells; TC, theca cell. for 3 times). Then the sections were incubated overnight at room temperature with each primary polyclonal antibody designed to recognize GDF8 (diluted at 1:100), ALK5 (diluted at 1:200), ACVR2A (diluted at 1:1000) or ACVR2B (diluted at 1:300). After rinsing, sections were incubated with 50 μl of Envision HRP secondary antibody (diluted at 1:1000) for 30 min at room temperature. Sections were further washed with PBS-T and incubated with the 50 μl fresh DAB (0.05%) for 10 min. Each slice was examined under the dissecting microscope before brown or red staining showing. After washing with running water, sections were stained with hematoxylin, 0.1% hydrochloric acid (for differentiation after hematoxylin). Finally, sections were washed and dehydrated by gradient alcohol, bleached with dimethylbenzene and sealed with neutral gum. Negative controls of each staining were not exposed to the primary antibody and were processed in the same condition as the examined specimens.
Analyses of immunohistochemical staining
All of the slides were assessed using a Leica microscope with commercial software (Leica Application Suite, Leica Microsystems GmbH, Wetzlar, Germany). Five views were selected randomly at 400× magnification for calculating the positive staining numbers of a particular cell in the cytomembrane or cytoplasm. The assessment of the distribution patterns and degree of immunohistochemistry (IHC) of each target was evaluated using a semiquantitative immunoreactive scoring system (IRS) designed by Remmele and Stegner [30] . Briefly, the IRS was calculated by multiplying optical staining intensity (graded as 0, none; 1, weak; 2, moderate; and 3, strong staining) and the percentage of the positively stained cells (0, =0%; 1, ≤10% of the cells; 2, 11-50% of the cells; 3, 51-80% of the cells; and 4, >80% of the cells) [30] . Therefore, the total score of each sample ranged from 0 to 12 with 0 to 1 indicating no staining (negative staining), 2 to 4 indicating moderate staining, and 6 to 12 indicating high staining. The slides were examined and reviewed in a blinded fashion by two independent, experienced investigators.
Statistical analysis
Histoscore results are presented as the mean ± SD and were analyzed with the use of a multiple comparisons test analyzed via a one-way analysis of variance followed by Tukey multiple comparison tests and a two-tailed t-test using PRISM software (GraphPad Software, Inc., San Diego, CA, USA).
In particular, one-way analysis of variance was used to compare the mean differences in 2 or more groups (GCs or theca cells (TCs) of 0-2 mm, 2-5 mm, and 5-10 mm follicles). The two-tailed t-test was used to compare the average difference between two groups in the same structure type (GCs vs. TCs or large luteal cells vs. small luteal cells). The Shapiro-Wilks test was used to check the normal distribution of the results. Statistical significance was defined as * P < 0.05, * * P < 0.01, and * * * P < 0.001. 
Results
Localization of GDF8, ACVR2A, ACVR2B, and ALK5 in the ovarian follicles and corpus luteum in normal ovaries
To test the IHC validations of the current experiments, both ovarian tissues from normal and PCOS women were used. Each negative IHC control for GDF8, ACVR2A, ACVR2B and ALK5, is shown in the supplementary Figures 1 (normal ovaries) and 2 (PCOS ovaries).
Immunostaining of normal human ovarian tissue sections with specific antibody to GDF8, ACVR2A, ACVR2B, and ALK5 indicated the presence of these immunoreactive proteins in several ovarian cell types. IHC localizations for GDF8, ACVR2A, ACVR2B, and ALK5 in the various cell types of human ovaries are summarized in Table 1 . The immunostaining of these proteins was distributed within the growing follicles and the surrounding stroma cells. Intense immunostaining was detected in large antral follicles. As was noted microscopically, we rarely observed the expression of these proteins in the cells on the ovarian surface. Specifically, the immunostaining of GDF8, ACVR2A, ACVR2B, and ALK5 was detected by IHC in oocytes of the primordial follicles ( Figure 1A , G, M and S). The immunostaining of GDF8, ACVR2A, ACVR2B, and ALK5 were detected in the oocytes of the ovarian follicles regardless of the developmental stage (<10 mm antral follicles) (Figure 1) . The immunostaining was detected in a few GCs of primary follicles (Figure 1B, H, N and T) . As shown in Figure 1 , the presence of GDF8, ACVR2A, ACVR2B, and ALK5 was localized in the GCs and TCs of 0-2 mm ( Figure 1C, I , O and U), 2-5 mm ( Figure 1D , J, P and V), and 5-10 mm ( Figure 1E , K, Q and W) antral follicles, respectively. Weak immunostaining of GDF8 was detected in the antral space of several antral follicles. Furthermore, these proteins were also localized in the large and small luteal cells of the corpus luteum in the normal ovaries ( Figure 1F , L, R and X). In the negative controls ( Supplementary Figure 1) , no signals were detected in any IHC. At higher magnification images (Figure 2 ), we found that GDF8 is localized in the oocyte of the primary follicle (Figure 2A ) and the GCs as well as the TCs of the antral follicles ( Figure 2C ). In addition, we could detect the immunostaining of GDF8 in the large and small luteal cells of the corpus luteum ( Figure 2D ).
Localization of GDF8, ACVR2A, ACVR2B, and ALK5 in the ovarian follicles of PCOS ovaries A very similar expression pattern was observed in the 14 PCOS specimens. Microscopic examination of the staining slides revealed that the immunostaining of GDF8, ACVR2A, ACVR2B, and ALK5 was detected by IHC in oocytes of the primordial follicles ( Figure 3A , F, K and P). Scant, usually weak expression was observed in some GCs of primary follicles ( Figure 3B , G, L and Q). Notably, the signal was consistently present in the oocytes of different ovarian stages (Figure 3) . In all the samples of PCOS ovaries, GDF8, ACVR2A, ACVR2B, and ALK5 staining was strongly detected in the GCs and TCs of various sizes (0-2 mm, 2-5 mm, and 5-10 mm) of antral follicles ( Figure 3C -E, H-J, M-O, and R-T). No signals were detected in the negative control IHC (Supplementary Figure 2) . The structure of the corpus luteum was not found in the specimens of PCOS ovaries. At higher magnification images (Figure 4) , we found that GDF8 is localized in the oocyte of the primary and antral follicles ( Figure 4A and B) . In addition, both GCs and TCs of various sizes of antral follicle intensively displayed GDF8 (Figure 4B-D) .
Progressive increases in the expression of GDF8, ACVR2A, ACVR2B, and ALK5 in both GCs and TCs of antral follicles in normal and PCOS ovaries To further evaluate the intensity and distribution patterns of the specific IHC, a semiquantitative method (IRS score) was used as previously described [30] . The total IRS scores of GCs and TCs in the different sizes (0-2 mm, 2-5 mm, and 5-10 mm) of antral follicles of normal and PCOS ovaries are listed in Table 1 . As the antral follicles mature, GDF8, ACVR2A, ACVR2B, and ALK5 expression appears to progressively increase, so that antral follicles show intense GC signal of these proteins in both normal and PCOS ovaries (P < 0.01, one-way analysis of variance) ( Figure 5) . A similarly increasing expression pattern occurs in the TC signal changes in these proteins during the growth of the antral follicles (P < 0.05, one-way analysis of variance) ( Figure 6 ).
GCs and TCs of antral follicles in PCOS ovaries display higher presence of GDF8, ACVR2A, ACVR2B, and ALK5
Compared to the normal ovaries, the immunoreactivity of GDF8, ACVR2A, ACVR2B, and ALK5 in GCs ( Figure 5 ) and TCs ( Figure 6 ) of both 2-5 mm and 5-10 mm antral follicles is significantly higher in PCOS ovaries (P < 0.05, two-tailed t-test), indicating stronger levels of these proteins. However, there was no significantly different expression of these proteins in the GCs or TCs of 0-2 mm antral follicles (Figures 5 and 6 ).
Granulosa cells display higher expression of GDF8, ACVR2A, ACVR2B, and ALK5 in 2-5 mm and 5-10 mm antral follicles Compared to the matched TCs, the expression of GDF8, ACVR2A, ACVR2B, and ALK5 was significantly higher in the GCs of 2-5 mm and 5-10 mm, but not 0-2 mm antral follicles of normal ovaries (P < 0.01, two-tailed t-test) (Figure 7) . Likewise, the expression of these proteins was higher in the GCs than those in the TCs of 2-5 mm and 5-10 mm, but not 0-2 mm antral follicles in PCOS ovaries (P < 0.001, two-tailed t-test) (Figure 8 ).
Large luteal cells display higher expression of GDF8, ACVR2A, ACVR2B, and ALK5 in the corpus luteum
To conduct further IHC analysis of these proteins, we included a wider range of corpus luteum stage in the normal ovaries. The results showed that the presence of GDF8, ACVR2A, ACVR2B, and ALK5 was detected in all the specimens examined and that the immunostaining levels of all targets were significantly higher in the large luteal cells than those in the small luteal cells (P < 0.05, two-tailed t-test) ( Figure 9 ).
Discussion
In the present study, we for the first time demonstrated the presence and localization of GDF8 and its receptors within the developing The results are expressed as box plots of medians and 25th and 75th percentiles with "n" indicating the sample number. Statistical significance of differences were determined using a multiple comparisons test analyzed via a one-way analysis of variance followed by Tukey multiple comparison tests and a two-tailed t-test.
* P < 0.05, * * P < 0.01, and * * * P < 0.001. ACVR, activin receptor; ALK, activin receptor-like kinase; GC, granulosa cell; IHC, immunohistochemistry.
human ovaries, suggesting a functional role for this locally produced growth factor in the regulation of ovarian folliculogenesis. Specifically, GDF8 and its receptors can be detected in most oocytes and are progressively expressed in follicle cells (GCs and TCs) of the antral follicles, indicating that GDF8 may play a critical role in regulating the growth and differentiation of oocytes, GCs and TCs. This dynamic change in the expression pattern of GDF8 and its receptors during the later stages of follicle development could implicate a potential role for this growth factor in the selection of a dominant follicle and the promotion of a mature oocyte. This assumption is supported by our recent in vitro studies demonstrating that GDF8 may modulate the maturation processes in the developing follicles by acting as both a maturation stimulator and a luteinization inhibitor [23] . In particular, treatment of human luteinized GCs with GDF8 increased the basal and FSH-induced estradiol production and decreased the basal and LH-induced progesterone production [23] . During folliculogenesis, the preantral follicles (0.1-0.2 mm) develop independently of gonadotropins until they grow up to 0.2-0.4 mm in diameter, a fluid-filled cavity (antrum) formed antral follicle, and follicles become responsive to gonadotropins [31] . Beyond this stage, the serum levels of estradiol and FSH begin to rise to promote the development of the dominant follicle by enhancing GC growth and differentiation as well as oocyte maturation [32] . Our data showed that the expression of GDF8 is positively correlated with the growth of antral follicles. This finding is consistent with the results of our previous study, as we have demonstrated that GDF8 can increase the production of estradiol and enhance the GC responsiveness to FSH [23] . Furthermore, the finding that there is a higher display of GDF8 in the GCs than in the TCs suggests a dominant role for GDF8 in regulating GC function. After ovulation, GCs differentiate into large luteal cells, and TCs differentiate into small luteal cells, and both cell types produce progesterone to establish endometrial decidualization. Interestingly, the current study also shows that GDF8 and its receptors are extensively localized in the luteal cells of corpus luteum, suggesting a potential role for GDF8 in regulating the luteal function. Consistent with the results from the IHC staining in the antral follicles, large luteal cells display higher expression of GDF8 and its receptors in the corpus luteum. Future in vitro functional studies or animal studies aimed at addressing the molecular mechanisms underlying the dysregulated GDF8 in the PCOS ovaries will be of great interest. Because of the heterogeneity of PCOS, a comprehensive understanding of the underlying mechanism and pathogenesis of this endocrine disorder is still lacking. Studies have shown that patients with PCOS often encounter ovulatory dysfunction and poor fertilization rates of their retrieved oocytes [33] . Studies using knock-out mice The results are expressed as box plots of medians and 25th and 75th percentiles with "n" indicating the sample number. Statistical significance of differences were determined using a multiple comparisons test analyzed via a one-way analysis of variance followed by Tukey multiple comparison tests and a two-tailed t-test.
* P < 0.05, * * P < 0.01, and * * * P < 0.001. ACVR, activin receptor; ALK, activin receptor-like kinase; IHC, immunohistochemistry; TC, theca cell.
have shown that target depletion of Ptx3 results in abnormal cumulus expansion, failed in vivo fertilization and infertility [34] . Data from clinical samples indicate that the expression levels of PTX3 are closely correlated with both the quality and fertilization rates of the residing oocytes [35] . Interestingly, serum GDF8 concentrations are higher in obese women with PCOS [22] . Indeed, our recent study has demonstrated that GDF8 may inhibit cumulus expansion by downregulating PTX3 expression [26] . Data from clinical studies have shown that the serum PTX3 levels are lower in women with PCOS [36] . The current study reveals that GDF8 is localized at a higher level in the GCs of PCOS ovaries than that in the GCs of normal ovaries. Collectively, these data suggest that high expression of GDF8 in the GCs may downregulate PTX3 expression and inhibit cumulus expansion, which contributes to the phenotypes of ovulatory dysfunction and poor fertilization rate in patients with PCOS. However, further works are required to examine the correlation of GDF8 and PTX3 in the pathogenesis of PCOS.
Another common characteristic hallmark of PCOS patients is the defect of TC androgen synthesis leading to an increase in ovarian androgen production. In addition to the different expression of GDF8 in the GCs, our study also demonstrated that GDF8 immunostaining levels are higher in the TCs of PCOS ovaries, indicating that GDF8 may be involved in the process of androgen synthesis in TCs. Indeed, our previous works have shown that GDF8 is a modulator for GC steroidogenesis. Specifically, GDF8 increases estradiol production by upregulating P450 aromatase expression and decreases progesterone production by downregulating steroidogenic acute regulatory protein expression in normal human granulosa-lutein cells [23] . However, we did not demonstrate the effect (stimulatory or suppressive) of GDF8 on the production of androgen because of lacking appropriate cell model (TCs). Whether the elevated GDF8 may affect the production of estradiol and androgen in PCOS ovaries remains to be elucidated. At present, the functional assessment of whether GDF8 regulates androgen synthesis in human TCs is still lacking because of the feasibility of obtaining these cells. Future works using animal models to study the functional role of GDF8 in the regulation of androgen production in the TCs will be of great interest.
The results presented in this study reveal that GDF8 and its receptors are highly present in both the GCs and TCs of the PCOS ovaries than in the normal ovaries, suggesting a distinct role for GDF8 in the pathogenesis of PCOS. Women with PCOS are often characterized by LH hypersecretion due to the increases in both the LH pulse frequency and amplitude, which in turn, results in an increase in TC androgen production [37] . Currently, the information regarding the regulation of GDF8 expression and activity is limited. In skeletal muscles, GDF8 initiates its action through the binding to The results are expressed as mean ± SD with "n" indicating the sample number. Statistical significance of differences were determined using a two-tailed t-test.
* P < 0.05, * * P < 0.01, and * * * P < 0.001. ACVR, activin receptor; ALK, activin receptor-like kinase; GC, granulosa cell; IHC, immunohistochemistry; TC, theca cell. The results are expressed as mean ± SD with "n" indicating the sample number. Statistical significance of differences were determined using a two-tailed t-test. * P < 0.05, * * P < 0.01 and * * * P < 0.001. ACVR, activin receptor; ALK, activin receptor-like kinase; GC, granulosa cell; IHC, immunohistochemistry; TC, theca cell. ACVR2A or ACVR2B, and this binding could be inhibited by an activin-binding protein follistatin, which antagonized the function of GDF8 on muscle growth [38] . In ovarian antral follicles, whether gonadotropins (FSH and LH) or androgen regulate the expression or activity of GDF8, which contributes to the elevated GDF8 expression in PCOS ovaries, remains to be elucidated. A previous ovarian immunostaining study using five size-matched populations of isolated preantral follicles has shown that GDF8 functional receptors (ACVR2A, ACVR2B, and ALK5) are all consistently expressed throughout each of the follicle groups in human developing follicles [29] . Our result showing that these receptors are increasingly expressed in PCOS ovaries could imply that the elevated GDF8 expression in PCOS ovaries may have a profound cellular effect on follicular function via the interaction with these receptors that cause the pathological phenotypes of this endocrine disease.
In conclusion, we found that the human ovary is a tissue of presence of GDF8, ACVR2A, ACVR2B, and ALK5, especially in the antral follicles. These proteins are extensively localized at the oocytes, GCs, and TCs, suggesting an autocrine and/or paracrine mode of action for GDF8 within the developing ovary. Progressively increased expression of GDF8 and its receptors within the antral follicles may reflect a functional role for GDF8 in establishing and maintaining the cellular interactions between follicle cells and germ cells during the development of ovarian follicles. Additionally, the consistent existence of GDF8 in the corpus luteum suggests a potential role in luteal function. Furthermore, a particularly high presence of GDF8 detected in GCs and large luteal cells highlights the dominantly functional site and activity of this intraovarian growth factor. Our findings showed that GDF8 expression is increasing in both GCs and TCs in PCOS ovaries compared with that in normal ovaries. The overexpression of GDF8 could be involved in ovulatory dysfunction, follicular growth arrest, and metabolic disorders associated with the various phenotypes of PCOS.
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